From magic bullets to designed multiple ligands (Q35848618)

10 August 2017

1 reference

title

From magic bullets to designed multiple ligands (English)

1 reference

10 August 2017

Richard Morphy

1

1 reference

10 August 2017

Corinne Kay

series ordinal

2

1 reference

10 August 2017

Zoran Rankovic

series ordinal

3

1 reference

10 August 2017

language of work or name

1 reference

1 August 2004

1 reference

10 August 2017

1 reference

10 August 2017

9

1 reference

10 August 2017

15

1 reference

10 August 2017

641-651

1 reference

Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

New targets for antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

A new class of ibuprofen derivatives with reduced gastrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

"Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Design and synthesis of a novel synthetic NAPAP-penta-saccharide conjugate displaying a dual antithrombotic action.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

First dual NK(1) antagonists-serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Selective optimization of side activities: another way for drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Indoline and piperazine containing derivatives as a novel class of mixed D(2)/D(4) receptor antagonists. Part 2: asymmetric synthesis and biological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Dual D2-receptor and beta2-adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethyl)-4-hydroxybenzothiazol-2(3H)-one analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Molecular properties that influence the oral bioavailability of drug candidates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Is there a difference between leads and drugs? A historical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Synthesis and NK(1)/NK(2) binding activities of a series of diacyl-substituted 2-arylpiperazines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Synthesis and structure-activity relationships of 4-amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Dual angiotensin converting enzyme/thromboxane synthase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Synthesis of [[(benzenesulfonamido)alkyl]phenyl]alkanoic acid derivatives containing pyridyl or imidazolyl groups and their thromboxane A2 receptor antagonistic and thromboxane A2 synthase inhibitory activities

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

DPI-3290 [(+)-3-((α-R)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A Mixed Opioid Agonist with Potent Antinociceptive Activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

The design and synthesis of novel NK1/NK2 dual antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Dipeptide sulfonamides as endothelin ETA/ETB receptor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Large Dimeric Ligands with Favorable Pharmacokinetic Properties and Peroxisome Proliferator-Activated Receptor Agonist Activity in Vitro and in Vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

Systematic discovery of multicomponent therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2804%2903163-0

7 January 2021

10.1016/S1359-6446(04)03163-0

Identifiers

DOI

1 reference

10 August 2017

1 reference